The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and ...
Read more
The Aortyx team is developing a minimally invasive solution for aortic dissection, essentially a tear in the aortic wall. To this end, they have created a steerable catheter that is inserted through t...
Read more
The funds come from new investors like the EIC Fund and CDTI Innvierte, as well as from existing investors AdBio Partners, Columbus Venture Partners, Invivo Partners and Takeda Ventures, which continu...
Read more
Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertis...
Read more
Highlight Therapeutics is a Spanish biotechnology company specialising in immuno-oncology, focused on the development of innovative cancer therapies. Its lead investigational compound, BO-112, is a do...
Read more
Batea Oncology has developed GlioHook, an innovative medical device implanted during surgery that captures residual tumor cells responsible for relapse and makes them more sensitive to standard radiot...
Read more
FreeOx has developed the first cerebroprotective therapy designed to preserve the brain during acute ischemic stroke. It is the key piece in stroke treatment, as it focuses on microcirculation and sol...
Read more
Nanoligent is a company whose goal is to develop new anticancer drugs specifically targeting aggressive tumors, using a pioneering technological platform based on protein–drug nanoconjugates. The co...
Read more
Ona Therapeutics is a pioneer in the development of first-in-class antibody-drug conjugates (ADCs) that leverage the molecular basis of advanced cancer. Through collaboration with academic and clinica...
Read more
Atlas Molecular Pharma (Atlas), a biotechnology company and spin-off of CIC bioGUNE, has closed a €3 million investment round aimed at driving the clinical development of ATL-001, its oral clinical-...
Read more
Tetraneuron has developed a gene therapy platform based on E2F4DN, a dominant-negative form of the transcription factor E2F4. According to the company, this is a revolutionary approach, as it acts at ...
Read more
La estrategia de inversión especializada ha permitido capitalizar el gran potencial de la innovación biomédica, impulsada además por una oleada de fusiones y adquisiciones.
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Telum Therapeutics, a biotechnology company leveraging proprietary met...
